Global neurometabolic disorders market is anticipated to exhibit lucrative market growth over the forecast period owing to increasing prevalence of neurometabolic disorders. The growth in institutional and research fields, which work at the core level of disease progression such as metabolomics, transcriptomics, lipidomics, and proteomics, is expected to develop more advanced diagnostics and treatment, thus leading to positive impact on market growth. The launch of new drug treatment regimens coupled with increased patient and physician awareness are high impact rendering drivers for the market.
Browse full research report on Global Neurometabolic Disorders Market:
Neurometabolic disorders market is analyzed on the basis of routes of administration and types. The route of administration segment is bifurcated into parenteral and oral routes. Oral route segment held substantial position in the market in 2014 pertaining to the convenience of administration, it provides to the patients. Oral route segment is also expected to continue its dominance in the coming seven years owing to the presence of various products in the pipeline. On the basis of type, it is divided into mucopolysaccharidosis VI, pompe, fabry, gaucher’s, and niemann-pick type c disease. As of 2014, gaucher’s disease segment held the substantial share owing to increased awareness about the disease and availability of the convenient treatments such as enzyme replacement therapy. Fabry disease segment is expected to grow at a lucrative rate over the forecast period owing to the novel drugs such as Plicera in pipeline.
Request for TOC of this research report:
Amongst the five regions, North America held the largest share in the neurometabolic disorders market owing to various growth factors such as advanced research projects for disease study and treatment. The other factors include allowance of economic leverages and market exclusivity provision for the diagnostic and prophylactic companies involved in neurometabolic market. Asia Pacific is expected to be the fastest growing region over the forecast period owing to improving healthcare expenditures pattern and rising need of novel drugs. Increasing number of new market players are anticipated to play a significant role in growth of neurometabolic disorders market in this region over the forecast period.
Browse more reports of this category by Grand View Research:
Major players of the neurometabolic disorders market are Amicus Therapeutics, JCR Pharmaceuticals, ISU Abxis, Greenovation Biotech, Biosidus., UAB Proforma, Dong-A Socio Group, Neuraltus Pharmaceuticals, ExSAR Corporation, Lixte Biotechnology Holdings, Inc, Protalix BioTherapeutics, Pharming Group N.V, Genzyme, Greencross, and Biomarin. These companies are involved in developing products that provide maximum benefit to the patients. For instance, Amicus Therapeutics focuses on the development of pharmacological chaperones for the treatment of neurometabolic disorders that can be administered orally.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information, visit: www.grandviewresearch.com
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: email@example.com, firstname.lastname@example.org
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States